ESSA Pharma (EPIX) said late Thursday it decided to terminate the phase 2 trial evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide alone.
Shares slumped 71%, with intraday trading volume at over 27.6 million compared with a daily average of about 59,000.
Lexicon Pharmaceuticals (LXRX) said late Thursday that the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration voted 11-3 against recommending Zynquista (sotagliflozin) as an add-on to insulin therapy for glycemic control in adults suffering from type 1 diabetes and chronic kidney disease.
Shares sank 37% as intraday trading volume catapulted to more than 16.8 million from a daily average of about 2.7 million.
Autonomix Medical (AMIX) unveiled Friday the launch of a public offering of up to 698,812 common stock units at $14.31 each.
Shares retreated 24%, with intraday trading volume at over 341,000 versus a daily average of roughly 451,000.
Price: 1.52, Change: -3.68, Percent Change: -70.77
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。